The number of people with Alzheimer’s disease, a degenerative brain disease and the most common form of dementia, will rise by at least 14% in all 50 states over the next eight years. However, the rate of increase will be higher in some states than others, according to a recent report from the Alzheimer’s Association, placing greater financial stress on health care programs and boosting the need for caregivers.

Alaska is projected to have the biggest increase in Alzheimer’s cases, from 7,100 in 2015 to 11,000 in 2017, or a 54.9% jump. Arizona, Nevada, Vermont, and Utah round out the top five with projected increases of at least 40% each. Iowa is expected to have the lowest increase, from 64,000 to 73,000, or 14.1%.

41. Pennsylvania
> Increase in Alzheimer’s, 2017-2025: 18.5%
> Pct. of 65+ pop. with Alzheimer’s: 12.4% (10th highest)
> Population 65+: 17.0% (6th highest)
> Pct. of 65+ pop. in good health: 75.7% (22nd lowest)
> Avg. retirement income: $21,263 (10th lowest)

The number of 65 and over people in Pennsylvania, who currently comprise 17% of the population, is expected to grow by less than 20% by 2025, nearly the slowest projected elderly population growth of all states.

Medicaid costs for caring for people with Alzheimer’s disease in Pennsylvania are estimated to be $3.23 billion in 2017. Alzheimer’s-related Medicaid spending is projected to increase by only 20.7% in the next eight years, the smallest projected spending growth of any state. Lower Medicaid costs for elderly populations are generally expected in states with lower projected increases in Alzheimer’s cases.

24/7 reviewed the Alzheimer’s Association “2017 Alzheimer’s Disease Facts and Figures” report to find for each state the projected percentage increase in the number of people with Alzheimer’s over the next eight years. States in the West and Southeast are expected to have the largest percentage increases in the number of people with Alzheimer’s between 2017 and 2025.

Click here to see the states where people will suffer the most from Alzheimer’s.
Click here to see our detailed findings and methodology.